Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Antihypertensive drugs and the risk of incident rosacea.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2828675
Author(s) Spoendlin, J; Voegel, J J; Jick, S S; Meier, C R
Author(s) at UniBasel Meier, Christoph R.
Year 2014
Title Antihypertensive drugs and the risk of incident rosacea.
Journal British journal of dermatology
Volume 171
Number 1
Pages / Article-Number 130-6
Abstract Despite scarce evidence, use of calcium channel blockers is discouraged in patients with rosacea, whereas beta-blockers are recommended as an off-label treatment for erythematotelangiectatic rosacea.; To study the association of the use of calcium channel blockers, beta-blockers and other antihypertensive drugs with incident rosacea.; We conducted a matched case-control study of antihypertensive drugs and incident rosacea, using the U.K.-based General Practice Research Database. Cases had an incident diagnosis of rosacea recorded between 1995 and 2009. Each case was matched to one control on age, sex, general practice and years of history on the database before the index date. Drug use was stratified by timing (≤ or > 180 days before the index date) and duration (number of prescriptions) of drug exposure, in a multivariate conditional logistic regression model.; Among 53 927 cases and 53 927 controls, we observed odds ratios (ORs) around unity for calcium channel blockers across all strata, with a slightly decreased OR of 0·77 (95% CI 0·69-0·86) for current users of dihydropyridine calcium channel blockers with ≥ 40 prescriptions. Among beta-blockers, atenolol and bisoprolol yielded slightly decreased ORs across all exposure strata, whereas propranolol revealed ORs around 1·0, irrespective of timing and duration of exposure. Neither angiotensin-converting-enzyme inhibitors nor angiotensin receptor blockers altered the relative rosacea risk.; Our data contradict the prevailing notion that calcium channel blockers increase the risk of rosacea. Beta-blocker use was associated with a slightly decreased risk of rosacea, but the effect may be somewhat stronger in patients with erythematotelangiectatic rosacea.
Publisher Lewis
ISSN/ISBN 0007-0963
edoc-URL http://edoc.unibas.ch/dok/A6337882
Full Text on edoc No
Digital Object Identifier DOI 10.1111/bjd.12838
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/24428524
ISI-Number WOS:000344001300023
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.514 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
29/03/2024